Pluristem Therapeutics Inc. news

   Watch this stock
Showing stories 1 - 10 of about 67   

Articles published

PSTI 2.95 +0.01 (0.34%)
price chart
Pluristem Therapeutics, Inc. (PSTI) in Focus: Stock Up 7.4%
Pluristem Therapeutics, Inc. (PSTI - Snapshot Report) was a big mover last session, as the company saw its shares rise over 7% on the day.
Pluristem Therapeutics, Inc. (PSTI) in Focus: Stock Up 7.4% - Tale of the Tape
Pluristem Therapeutics, Inc. ( PSTI ) was a big mover last session, as the company saw its shares rise over 7% on the day.
Pluristem rebuffs patent challenge (PSTI)  Seeking Alpha (registration)
Pluristem Therapeutics Inc. (NASDAQ:PSTI) PLACENTA TISSUES Therapy ...  WallStreetPR (blog)
Related articles »  
Coverage Initiation Report Focuses on Pluristem Therapeutics
NEW YORK, NY--(Marketwired - Oct 1, 2014) - Pluristem Therapeutics Inc. ( NASDAQ : PSTI) ( TASE : PLTR) is the subject of a new in-depth initiation coverage report by Acceleron Equity Research.
Related articles »  
Pluristem Therapeutics Coverage Initiated by Analysts at Oppenheimer (PSTI)
Pluristem Therapeutics Inc. logo Oppenheimer began coverage on shares of Pluristem Therapeutics (NASDAQ:PSTI) in a research note released on Monday.
Oppenheimer Initiates Coverage on Pluristem Therapeutics (PSTI)  sleekmoney
Related articles »  
Pluristem Therapeutics (PSTI) Releases Quarterly Earnings Results
Pluristem Therapeutics logo Pluristem Therapeutics (NASDAQ:PSTI) issued its quarterly earnings data on Monday. The company reported ($0.09) earnings per share for the quarter, beating the analysts' consensus estimate of ($0.13) by $0.04, ...
Zacks Upgrades Pluristem Therapeutics to "Outperform" (PSTI)  Ticker Report
Latest Developments: Pluristem Therapeutics Inc. (NASDAQ:PSTI), Vale SA ...  Market News Call
Related articles »  
Pluristem Therapeutics Now Covered by Oppenheimer (PSTI)
Pluristem Therapeutics Inc. logo Investment analysts at Oppenheimer initiated coverage on shares of Pluristem Therapeutics (NASDAQ:PSTI) in a note issued to investors on Monday.
Pluristem Therapeutics COO Yaky Yanay Purchases 11000 Shares (PSTI)  Intercooler
Related articles »  
Pluristem Therapeutics Rating Increased to Outperform at Zacks (PSTI)
Pluristem Therapeutics Inc. logo Zacks upgraded shares of Pluristem Therapeutics (NASDAQ:PSTI) from a neutral rating to an outperform rating in a research report sent to investors on Monday morning.
Market Highlight: Pluristem Therapeutics (PSTI), Christopher & Banks ...  USMarketsDaily (blog)
Stocks Alert- Pluristem Therapeutics Inc. (NASDAQ:PSTI), Tetraphase ...  Techsonian (press release)
Related articles »  
Pluristem Therapeutics COO Buys $32450 in Stock (PSTI)
Pluristem Therapeutics Inc (NASDAQ:PSTI) is a bio-therapeutics company engaged in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders.
Biotech Insider Buying : Exelixis (NASDAQ:EXEL), La Jolla Pharmaceutical Co ...  WallStreet Scope
Related articles »  
Pluristem Therapeutics Earns Outperform Rating from Analysts at Oppenheimer ...
Pluristem Therapeutics Inc. logo Oppenheimer began coverage on shares of Pluristem Therapeutics (NASDAQ:PSTI) in a research note issued to investors on Monday morning.
Market Movers: National Bank of Greece (NYSE:NBG), Cisco Systems (NASDAQ ...  WallStreet Scope
Related articles »  
Pluristem Therapeutics Sees Strong Trading Volume on Insider Buying Activity ...
Pluristem Therapeutics logo Pluristem Therapeutics (NASDAQ:PSTI) shares saw strong trading volume on Wednesday after an insider bought additional shares in the company, AnalystRatingsNetwork reports. 302,219 shares were traded during mid-day ...
Related articles »